blocker

(redirected from sodium channel blocker)
Also found in: Dictionary, Thesaurus.

blocker

 [blok´er]
something that blocks or obstructs a passage or activity; see also antagonist and blocking agent.
β-blocker (beta-blocker) beta-adrenergic blocking agent.
calcium channel blocker calcium channel blocking agent.
potassium channel blocker potassium channel blocking agent.
sodium channel blocker sodium channel blocking agent.

block·er

(blok'er),
An instrument used to obstruct a passage.

blocker

/block·er/ (blok´er) something that blocks or obstructs passage, activity, etc.
α-blocker  alpha-adrenergic blocking agent; see adrenergic blocking agent.
β-blocker  beta-adrenergic blocking agent; see adrenergic blocking agent.
calcium channel blocker  calcium channel blocking agent.
potassium channel blocker  potassium channel blocking agent.
sodium channel blocker  sodium channel blocking agent.

blocker

blocker

A popular term for anything which physically (e.g., a bed blocker, see there) or pharmacologically (e.g., a beta-blocker) impedes a process or activity.

block·er

(blok'ĕr)
1. An instrument used to obstruct a passage.

blocker

something that blocks or obstructs passage, activity, etc.

α-blocker, alpha-blocker
a drug that induces adrenergic blockade at α-adrenergic receptors.
β-blocker, beta-blocker
a drug that induces adrenergic blockade at either β1- or β2-adrenergic receptors, or both (see also beta-blocker).
calcium channel blocker
a drug that selectively inhibits the influx of calcium ions through a specific ion channel of cardiac muscle and smooth muscle cells (see also calcium channel blocker).
H2-receptor blocker
a drug, such as cimetidine that inhibits the secretion of gastric acid stimulated by histamine, pentagastrin, food and insulin, and also basal secretion; used in the treatment of peptic ulcer.
References in periodicals archive ?
Spontaneous type 1 ECG, independently of history of syncope, predicted a higher risk in experiencing SCD than a non-diagnostic ECG which converted to coved-type ECG by exposure to sodium channel blockers during a mean follow-up of 24 [+ or -] 32 months.
By screening a range of novel proprietary molecules from the Convergence pipeline, and also existing sodium channel blockers currently used in clinical practice to treat neuropathic pain, this collaborative venture will build a rationale for future clinical studies, through pharmacological validation of genetically defined patient groups.
Current therapies are centred on sodium channel blockers such as carbamazepine or oxcarbazepine as first-line treatments.
Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel analgesic medicines for the treatment of chronic pain, today announces positive interim data from the ongoing Phase II clinical trial of novel sodium channel blocker CNV1014802 in patients with trigeminal neuralgia (TN), a very severe form of facial pain.
Eslicarbazepine acetate (ESL) is a novel voltage-gated sodium channel blocker.
Food and Drug Administration (FDA) approval for Ranexa, a first-in-class late sodium channel blocker and the first anti-anginal drug class approved in 30 years.
Title: Ocular Pharmacokinetics of P-321, a Novel Long-Acting Epithelial Sodium Channel Blocker Session Name: Poster Session #376, Dry Eye Disease #2 Poster Number: #A0207 Session Date and Time: Tuesday, May 6, 3:45 p.
14, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the first subjects were dosed in a Phase 1 clinical study for NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain.
Ralfinamide is a novel compound of the alpha-aminoamide family with potent sodium channel blocker properties.
The Company's lead compound, Tetrodotoxin, a sodium channel blocker, is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.
Recently, we have introduced a way to target the delivery of sodium channel blockers selectively to nociceptive neurons, and thus capitalize on their effectiveness in blocking action potentials but now only at sites of pain generation.

Full browser ?